So far, the FDA has primarily approved treatments for AD that focus on compensating for cholinergic neuron loss using drugs such as inhibitors for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), including medications like tacrine, donepezil, rivastigmine, and galantamine, as well as the glutamatergic drug memantine, which functions as an N-methyl-D-aspartate (NMDA) receptor antagonist (Albertini et al
The IHC staining patterns are shown in Fig
20254088), Key Program of National Natural Science Foundation of China (No
Wait at least 2-3 hours after eating before injecting, and avoid food for 30-60 minutes afterward
In gene expression profiling, GHK-Cu treatment of human fibroblasts upregulated superoxide dismutase (SOD1, SOD2, SOD3) and glutathione-related genes while suppressing NF-kB-driven inflammatory signaling [3]